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Chapter 9
Dose escalation of dacarbazine combined with interferon-alfa,
G-CSF and ondansetron in patients with metastatic melano-
ma
J. Buter, D. Th. Sleijfer, P.H.B. Willemse, W.T.A. van der Graaf, E.G.E. de Vries,
H. Schraffordt Koops1 and N.H.Mulder.
Departments of Internal Medicine and 1Surgery, University Hospital, Groningen, 9713 EZ
The Netherlands.
Summary
To define the activity of an individually escalated dacarbazine (DTIC) dose combined with
interferon alfa-2a (IFN), granulocyte-colony stimulating-factor (G-CSF), and ondansetron, 20
patients with metastatic melanoma, were treated with DTIC, ondansetron 8 mg iv. G-CSF 300
µg sc. and IFN 9x106 IU sc. Treatment every 21 days to a maximum of 6 courses. DTIC dose
was escalated with 250 mg/m² in case of acceptable toxicity to 1250, 1500 and 1750 mg/m2
in 14/19, 8/11 and 0/5 patients, respectively. Dose escalation prohibiting toxicities were
thrombopenia (10 pts.), leucopenia (9 pts.) and nausea/vomiting (2 pts.). Four partial remis-
sions were observed, for a response rate of 20% (95% confidence interval, 6 to 44 %).
Duration of responses were 1, 2, 3, and 3 months. Median overall survival was 7.8 months.
Introduction
Approximately 20% of the patients with malignant melanoma will develop distant metastases
that are not amenable to surgical therapy. The prognosis in this situation is poor with a
median survival of only a few months. No medical treatment is available that has substantial
influence on the prognosis of these patients. Chemotherapy is only marginally active with no
influence on survival. Dacarbazine (DTIC) is the most active chemotherapeutic drug with a
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low but consistent response rate of 17% (13 to 21%, 95% confidence interval) and a complete
response rate of approximately 5% in single-agent regimens (1-4). Interferon-alpha (IFN) has
shown therapeutic activity in patients with metastatic malignant melanoma. Response rates are
reported between 10 and 20% (5,6). When combined with DTIC, IFN has shown to improve
response rates and survival in patients with metastatic melanoma in several phase II trials for
response rates of 25 to 35 % (7-13). This could be confirmed in comparative studies. Toxicity,
particularly myelotoxicity, was more prominent with combination treatment in all studies
(14-16).
Besides the combination of agents, their individual dose intensity is an important
parameter for the outcome of systemic treatment of patients with disseminated solid tumors
(17). In melanoma patients this was also shown for the alkylating drug melfalan (18). At
standard DTIC dose of 800 mg/m² bolus i.v. on day 1 every 3 to 4 weeks, acute
nausea/vomiting (N/V) and leucopenia are dose limiting toxicities. With the recent availability
of new drugs that are capable of reducing side effects of chemotherapy, dose intensification
of DTIC might become possible in an attempt to improve therapeutic activity. Chemotherapy
induced nausea and vomiting can efficiently be reduced with the new 5 HT3-antagonistic anti-
emetics. Secondly, the growth factor G-CSF has been approved for reducing chemotherapy
induced neutropenia. In a phase II trial we studied the feasibility and efficacy of individual
DTIC dose intensification, combined with IFN under support of G-CSF and ondansetron in
patients with metastatic melanoma.
Materials and methods
Twenty patients were entered, all had histologically proven disseminated malignant melanoma
with measurable disease and met the following criteria: Age of 18 - 75 year, World Health
Organization (WHO) performance status 2 or less, expected survival of at least 3 months,
serum creatinine level < 150 µmol/L; serum bilirubin level < 25 µmol/L, WBC > 3.0x109/L,
platelet count > 100x109/L, and no prior treatment with dacarbazine or interferon. Patients
with brain metastases, other malignancies or uncontrollable disease were excluded. The study
protocol was approved by the Medical Ethical Committee and informed consent was obtained
from all patients before entry. Initial diagnostic workup consisted of a complete history and
physical examination, full blood counts and assessment of renal and hepatic function, chest
x-ray radiograph with additional computed tomography or sonography of abdominal masses
and from the liver in case of disturbed liver functions (1.5 times normal). Brain computed
tomography was done in case of clinical suspicion of brain metastases.
The maximal individual tolerated DTIC dose was given in combination with IFN and
supportive treatment with G-CSF and ondansetron. Patients received a starting dose of DTIC
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Table 1. Patients’ characteristics
N %
Patients 20
Female/male 7 / 13













Soft tissue and visceral 13 65
Bone 3 15
Lymph nodes 3 15
Other 2 10
Number of metastatic sites
1 11 55
2 6 30
3 or more 3 15
* May be more than one site IU s.c.
1000 mg/m² intravenously as a one hour infusion preceded by ondansetron 8 mg i.v. on day
1. Granulocyte colony-stimulating factor 300 µg was administered subcutaneously on day 3
through 13. Courses were repeated every 21 days to a maximum of 6 courses. Interferon-alfa-
2a was administered at a daily dose of 3 x 106 IU s.c. daily on day 1 to 3, and 9 x 106
thereafter during the whole treatment period. In the first seven patients IFN was started in
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1250 19 14 4 4
1500 11 8 2 1
1750 5 0 4 4 2
course 4, whereas the following patients received IFN from the first course of treatment.
DTIC dose was escalated with 250 mg/m² in a next course in case of bone marrow toxicity
less than WHO grade 3 and organ toxicity less than WHO grade 2. In those patients in which
IFN was started in course 4, no dose escalation of DTIC was performed in that course.
Acetaminophen (250-500 mg orally every 4-6 hours) was given to suppress pyretic reactions.
Patients were examined for toxicity on days 1, 15 and 22 of each course. Toxicity was
assessed using the WHO guidelines (19). For nausea and vomiting a modified grading was
used because of the prophylactic use of antiemetic medication. Grade 0 stated no complaints;
grade 1, nausea only; grade 2, nausea and vomiting 1-2 times; grade 3, nausea and vomiting
3 times or more, requiring additive medication; grade 4, intractable vomiting requiring
intravenous fluids.
DTIC dose was reduced to 75% of the previous dose in case of bone marrow toxicity
grade 4 in the preceding course or leucocytes of < 2.5 x109/L or thrombocytes < 100 x 109/L
on the day of DTIC infusion. When on the day of infusion, leucocytes were < 1.5 x109/L or
thrombocytes < 75 x109/L, the course was delayed for one week to a maximum of 3 weeks.
Interferon dose was withheld for one day per week in case of intolerance.
Tumor measurements and radiological examinations were repeated after 3 courses and
at the end of treatment. After 3 courses, treatment was continued unless progressive disease
was apparent. Complete response (CR) was defined as the disappearance of all signs of
disease for at least 4 weeks. A partial response (PR) was defined as a decrease by at least
50% in the sum of the products of the largest perpendicular diameters of all measurable
lesions. Stable disease (SD) was defined as a situation with less than 50% decrease or less
than 25% increase and progressive disease (PD) as more than 25% increase in the sum of the
aforementioned diameters.
Leucocyte numbers on days 1, 15 and 22 of course 1 to 3 in which the first 7 patients
140
did not receive IFN were compared with those of the following 7 patients who started with
Table 3. Percentage of courses with toxicity occurring in 66 assessable courses
Toxicity WHO grade
1 2 3 4
Nausea/vomiting 36 20 5
Diarrhoea 12 2
Fatigue 30 15 2
Leucopenia 32 11 12 2
Thrombocytopenia 6 10 12 8
Anemia 15 11 5 2
Neurotoxicity 23 12 2
IFN from the start of treatment to study the influence of IFN on G-CSF stimulation of
leucocytes.
Statistics
Differences in leucocyte numbers were tested using the Mann-Whitney-U test.
Results
Patients
The clinical characteristics of the patients entered in this protocol are summarized in table 1.
The 20 patients were treated with 1 to 6 courses (median 3) for a total of 65 courses. All
patients completed at least one course and all patients were evaluable for toxicity.
Toxicity and dose escalation of DTIC
DTIC dose could be escalated to 1250, 1500 and 1750 mg/m2 in 14 of 19, 8 of 11 and 0 of
5 patients, respectively (Table 2.). Dose escalation prohibiting toxicities were thrombopenia
(10 patients), leucopenia (9 patients), and nausea and vomiting (2 patients). In 8 other patients
no dose escalation was attempted because of tumor progression. Toxicities occurring during
a total of 65 courses are listed in table 3. Grade 3/4 thrombopenia and leucopenia occurred
in 20% and 14% of the courses, respectively. Five patients received red blood cell transfusions
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and 4 patients received prophylactic platelet transfusions in the course of their treatment.
Nausea and vomiting grade 2 and 3 occurred in 22% and 6% of
Table 4. Leucocyte numbers with or without IFN, course 1-3
Leucocytes (x 109/L)
without IFN with IFN
Day Mean SD Mean SD
1000 mg/m2 DTIC
1 7.8 1.8 5.9 2.1
15 13.2 4.9 5.2 4.3
22 7.9 4.6 4.1 0.9
1250 mg/m2 DTIC
1 7.4 2.8 5.4 4.0
15 10.1 4.4 11.4 11.2
22 8.1 2.7 6.5 7.0*
1500 mg/m2 DTIC
1 8.2 1.4 3.5 0.3*
15 3.6 0.1 4.9 3.6
22 6.5 1.4 3.3 0.4
* P <.05, compared to no IFN, Mann-Whitney U test
the courses despite the prophylactic use of ondansetron. Diarrhoea was limited to grade 1-2
occurring in 14% of the courses. One patient became hypotensive during DTIC infusion with
temporary tachycardia. Subsequent ECG analysis showed a sinus rhythm with no signs of
ischemia and treatment could be continued under clinical observation. Flu-like symptoms and
fatigue occurred in 16 of the patients during IFN treatment. These symptoms were controllable
with acetaminophen in most patients. Neurotoxicity was recorded in 7 patients. Four patients
had mild headache and intermittent somnolence. Three other patients had severe headache,
severe fatigue with mental depression, and confusion, in one patient each. IFN was withheld
temporary for toxicities in 4 patients, while treatment was discontinued in 2 patients.
To study possible interference of IFN with the stimulation effect of G-CSF on
leucocyte numbers, the first 3 courses in the first 7 patients receiving no IFN were compared
with the first 3 courses of the following 7 patients who did receive IFN. Leucocyte numbers
are listed in table 4. Leucocyte numbers in courses with IFN were lower on day 22 after
DTIC 1250 mg/m2 and on day 1 of DTIC 1500 mg/m2 (P < .05).
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Response
Twenty patients were evaluable for response. Four partial responses were observed. Five
patients had stable disease and 11 patients showed progression. Objective response rate was
20%, ( 95% confidence interval, 6 to 44 %). Response durations were 1, 2, 3, and 3 months.
Responses occurred in the lung, lymph nodes, and skin metastases. Three out of the four
responders were women. Median survival of all patients was 7.8 months. Average relative
dose intensity of DTIC (17) of all patients was 360 mg/m2/week. No differences in relative
DTIC dose intensity between responders and non-responders was observed.
Discussion
The treatment of metastatic melanoma is still unsatisfactory. DTIC, with response rates of
approximately 17%, is one of the most active drugs in this disease available (20).
The working mechanism of DTIC is partly understood. DTIC has no cytotoxic activity by
itself; it has to be metabolized in liver cells to its active metabolites that probably mediate
cytotoxic activity both as antimetabolites and as alkylating agents. O6-methyl-deoxyguanosine
formation in DNA is thought to be a critical cytotoxic event of DTIC activity (21,22).
Combination with IFN has been shown to improve response rates and survival of DTIC with
reported response rates up to 35 % in several phase II (7-13) and comparative studies (14-16).
In most studies, DTIC has been administered at a dose of 800 to 1250 mg/m2 given as a
single infusion or fractionated over 2 to 5 days every 3 to 4 weeks. Acute nausea/vomiting
and myelotoxicity, especially leucopenia, are dose limiting in this setting. We studied the
possibility of escalating DTIC dose with support of two new drugs that are capable of
reducing chemotherapy induced side effects.
In this study, the growth factor G-CSF and the antiemetic ondansetron permitted
individual dose escalation of DTIC up to 1500 mg/m2 in a 3 week cycle regimen. However,
a dose of 1500 mg/m2 was only realized in 8 out of the total 20 patients, with thrombopenia
or leucopenia prohibiting dose escalation in 10 out of the remaining 11 patients. A starting
dose of 1250 mg/m2 seems to be feasible for further study in this setting. Acute nausea and
vomiting was effectively controlled by ondansetron, given at a single i.v. bolus-injection of
8 mg before the start of infusion. Although nausea/vomiting was not completely prevented,
grade 3 nausea and vomiting occurred in only 6% of the courses ( 4 patients) while no grade
4 nausea/vomiting was not observed. In the current study, IFN administered s.c. at a daily
dose of 9 MU, was tolerated somewhat less well when compared with a previous standard
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DTIC dose combination regimen with IFN (10), requiring dose modifications in 29% of the
patients. It is possible that in addition to the escalated DTIC dose this is caused by the
combination of biological agents.
Because biological response modifiers have shown to influence the stimulation effect
of G-CSF on the maturation of neutrophils in vitro (23,24) and IFN has been shown to
suppress neutrophil colony formation in vitro (25,26), the patients leucocyte numbers were
studied during courses with and without concurrent IFN treatment. We observed some
marginal interference of IFN with the stimulation effect of G-CSF on leucocyte numbers
(table 4.). Leucocyte numbers on day 22 of 1250 mg/m2 and on day 1 of 1500 mg/m2 DTIC
dose level were lower in the IFN containing courses (P < .05). However, these difference
were not clinically important. The response rate of 20% ( 6% to 44 %, 95% confidence
interval) of the current study does not appear to be superior to the activity of other DTIC/IFN
combinations with standard DTIC doses (7-13). As to the sites of response, all four responses
occurred in the lung, soft tissue or lymph nodes, while no responses were observed in the
bone, liver or visceral abdominal metastases. This reflects the normal pattern in this disease.
In conclusion: The use of G-CSF and ondansetron permits individual dose escalation
of DTIC up to 1500 mg/m2 every 3 weeks in patients with metastatic melanoma with
thrombopenia and leucopenia as the main dose limiting factors. A clinical unimportant
interference of IFN with the stimulation of leucocytes by G-CSF was found. With the use of
G-CSF and ondansetron, a dose of 1250 mg/m2 every 3 weeks is recommended as a starting
dose for DTIC, when combined with IFN. Escalation of DTIC dose did not seem to improve
the response rate or survival of patients with metastatic melanoma in this study.
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